Cyramzaâ€™s new cancer indications
The European Commission recently approved two new indications for ramucirumab (Cyramza), which blocks the formation of new blood vessels (angiogenesis) to malignancies.
Firstly, ramucirumab is now indicated in combination with docetaxel for adults with locally advanced or metastatic nonsmall cell lung cancer that progressed after platinumbased chemotherapy.
Secondly, ramucirumab, which blocks vascular endothelial growth factor, is now approved combined with FOLFIRI (irinotecan, folinic acid and 5-fluorouracil) for metastatic colorectal cancer that progresses on or after bevacizumab, oxaliplatin and a fluoropyrimidine.
Understand how fungal nail infections develop and help manage customer expectations around treatment
Upgrade your contraceptive consultations by exploring the interactive pack to learn about a daily oral contraceptive pill
Record my learning outcomes
Inspiring stories related to health, fitness and the pursuit of wellbeing
More like this
Discovery of four Covid-19 risk groups could help guide treatment
A risk identification tool uses the groupings to help clinical staff choose the best course of treatment for patients.
2 Min Article
Update your knowledge of erection problems with key learning updates from recent research
4 Min Module
Advising customers of a unique formulation for a blocked and runny nose from colds
Understand the differences between topical medication for nasal symptoms of the common cold, and topical medication for ongoing nasal problems
34 Min Module